Lipoprotein(a) predicts a new onset of chronic kidney disease in people with Type 2 diabetes mellitus

Diabetic Medicine

Volumn 33, Issue 5, 2016, Pages 639-643

  Yun, J S ^a   Ahn, Y B ^a   Song, K H ^b   Yoo, K D ^a   Park, Y M ^c   Kim, H W ^a   Ko, S H ^a  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPROTEIN A;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; LIPOPROTEIN BLOOD LEVEL; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NEW ONSET CHRONIC KIDNEY DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PROGNOSIS; PROSPECTIVE STUDY; BLOOD; COHORT ANALYSIS; COMPLICATION; DIABETIC NEPHROPATHIES; INCIDENCE; KIDNEY; MIDDLE AGED; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR; SOUTH KOREA; TEACHING HOSPITAL; UPREGULATION;

ADULT; AGED; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; GLOMERULAR FILTRATION RATE; HOSPITALS, TEACHING; HUMANS; INCIDENCE; KIDNEY; LIPOPROTEIN(A); LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; REPUBLIC OF KOREA; RISK FACTORS; UP-REGULATION;

EID: 84940910798     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12862     Document Type: Article

References (20)

1. Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009; 302: 412-423.
2. Kamstrup PR, Nordestgaard BG. Lipoprotein(a) concentrations, isoform size, and risk of type 2 diabetes: a Mendelian randomisation study. Lancet Diabetes Endocrinol 2013; 1: 220-227.
3. Mora S, Kamstrup PR, Rifai N, Nordestgaard BG, Buring JE, Ridker PM. Lipoprotein(a) and risk of type 2 diabetes. Clin Chem 2010; 56: 1252-1260.
4. Boes E, Fliser D, Ritz E, Konig P, Lhotta K, Mann JF et al. Apolipoprotein A-IV predicts progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 2006; 17: 528-536.
5. Kronenberg F. Epidemiology, pathophysiology and therapeutic implications of lipoprotein(a) in kidney disease. Expert Rev Cardiovasc Ther 2004; 2: 729-743.
6. Kronenberg F, Utermann G, Dieplinger H. Lipoprotein(a) in renal disease. Am J Kidney Dis 1996; 27: 1-25.
7. Song KH, Ko SH, Kim HW, Ahn YB, Lee JM, Son HS et al. Prospective study of lipoprotein(a) as a risk factor for deteriorating renal function in type 2 diabetic patients with overt proteinuria. Diabetes Care 2005; 28: 1718-1723.
8. Akanji AO, al-Shayji IA, Kumar P. Metabolic and anthropometric determinants of serum Lp(a) concentrations and Apo(a) polymorphism in a healthy Arab population. Int J Obes Relat Metab Disord 1999; 23: 855-862.
9. Shintani S, Kikuchi S, Hamaguchi H, Shiigai T. High serum lipoprotein(a) levels are an independent risk factor for cerebral infarction. Stroke 1993; 24: 965-969.
10. Ko SH, Song KH, Ahn YB, Yoo SJ, Son HS, Yoon KH et al. The effect of rosiglitazone on serum lipoprotein(a) levels in Korean patients with type 2 diabetes mellitus. Metabolism 2003; 52: 731-734.
11. Yun JS, Ko SH, Song KH, Yoo KD, Yoon KH, Park YM et al. Cardiovascular disease predicts severe hypoglycemia in patients with Type 2 diabetes. Diabetes Metab J 2015; 39: e14.
12. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612.
13. Park CW. Diabetic kidney disease: from epidemiology to clinical perspectives. Diabetes Metab J 2014; 38: 252-260.
14. Standards of medical care in diabetes 2014. Diabetes Care 2014; 37 Suppl 1: S14-80.
15. Ahn JH, Yu JH, Ko SH, Kwon HS, Kim DJ, Kim JH et al. Prevalence and determinants of diabetic nephropathy in Korea: Korea national health and nutrition examination survey. Diabetes Metab J 2014; 38: 109-119.
16. KDOQI Clinical Practice Guideline for Diabetes and CKD 2012 Update. Am J Kidney Dis 2012; 60: 850-886.
17. Kronenberg F, Lingenhel A, Lhotta K, Rantner B, Kronenberg MF, Konig P et al. Lipoprotein(a)- and low-density lipoprotein-derived cholesterol in nephrotic syndrome: Impact on lipid-lowering therapy? Kidney Int 2004; 66: 348-354.
18. Hervio L, Girard-Globa A, Durlach V, Angles-Cano E. The antifibrinolytic effect of lipoprotein(a) in heterozygous subjects is modulated by the relative concentration of each of the apolipoprotein(a) isoforms and their affinity for fibrin. Eur J Clin Invest 1996; 26: 411-417.
19. Keane WF. Lipids and the kidney. Kidney Int 1994; 46: 910-920.
20. Kostner KM, Marz W, Kostner GM. When should we measure lipoprotein (a)? Eur Heart J 2013; 34: 3268-3276.